Source - LSE Regulatory
RNS Number : 0885K
Argent Biopharma Limited
10 April 2024
 

 

Argent BioPharma Ltd

PDMR Notification

10 April 2024

ASX, LSE: RGT

 

Argent BioPharma Ltd ('Argent BioPharma' or 'the Company') wishes to advise that the following Persons Discharging Managerial Responsibilities (PDMR) have dealt with shares in Argent BioPharma, and this notification is made in accordance the UK Market Abuse Regulations.

 

1

Details of the person discharging managerial responsibilities/person closely associated

 

(a)

Name

Amir Polak

2

Reason for the notification

 

(a)

Position

 

Chief Pharmaceutical Development Officer

(b)

Initial notification/amendment

 

Initial

(c)

If amendment: reason

 

n/a

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor


Full name of entity

Argent BioPharma Limited

 


Legal Entity Identifier Code

213800HRE3FQJ6RK4H10

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; (iv) each place where transactions have been conducted

 

(a)

Description of the financial instrument, type of instrument

Fully Paid Ordinary Shares

(b)

Identification Code (ISIN)

 

AU0000326647

(c)

Nature of transaction

Disposal of Shares

(d)

Currency

Price

Volume

Total


AUD

0.43

200

86.00


AUD

0.43

3,300

1,419.00


AUD

0.44

2,000

880.00


Aggregated information


AUD

 

5,500

2,385.00

(e)

Date of transaction

 

8-10 April 2024

(f)

Place of transaction

 

On Market

 

 

-Ends-

 

Authorised for release by the Company Secretary, for further information please contact:

Argent BioPharma

Roby Zomer

CEO & Managing Director

+61 8 6382 3390

info@argentbiopharma.co.uk

 

Argent BioPharma

Rowan Harland

Company Secretary

+61 8 6382 3390

info@argentbiopharma.co.uk

UK IR/PR Advisers 

IFC Advisory

Graham Herring / Tim Metcalfe / Zach Cohen

+44 203 934 6630

argentbiopharma@investor-focus.co.uk

UK Brokers

Oberon Capital

Aimee McCusker / Adam Pollock

+44 203 179 5300

aimeemccusker@oberoninvestments.com adampollock@oberoninvestments.com 

About Argent BioPharma

 

Argent BioPharma is dedicated to meeting unmet medical needs by combining PolyPharmacology and Nanotechnology, aspiring to be a renowned global leader in the biopharmaceutical sector. Our mission centres on researching and developing ground-breaking treatments for worldwide health issues, guided by strategic principles such as pioneering life science advancements, ensuring global access, fostering continuous innovation, and striving for industry leadership.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHZZGMDKGLGDZM
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Argent Biopharma Limited (RGT)

0p (-2.94%)
delayed 16:57PM